Author

Rachel Elizabeth Cooke

Observed names: Rachel Cooke, Rachel E Cooke, Rachel E. Cooke

Institutions: Northern Health, Northern Hospital

Observed institutions: The Royal Melbourne Hospital, The University of Melbourne, Northern Health, Australian Cancer Research Foundation, Austin Hospital, Peter MacCallum Cancer Centre, The Alfred Hospital, Northern Hospital, Austin Health

ORCID: 0000-0001-5222-0433

Observed ORCID: 0000-0001-5222-0433

OpenAlex ID: A5071552703

Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells

2020 · Rachel Elizabeth Cooke, Kylie Margaret Quinn, et al. · Frontiers in Immunology · 43

PDF

Impact of age-, cancer-, and treatment-driven inflammation on T cell function and immunotherapy

2020 · Kylie M Quinn, Apriliana E R Kartikasari, et al. · Journal of Leukocyte Biology · 30

PDF

Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma

2016 · Rachel E. Cooke, Nicholas A. Gherardin, et al. · Journal of Translational Medicine · 24

PDF

Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning

2016 · Masa Lasica, Emma Taylor, et al. · European Journal Of Haematology · 22

Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)

2021 · Krystal Bergin, Cameron Wellard, et al. · Bone Marrow Transplantation · 17

Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma

2020 · Sridurga Mithraprabhu, Anna Kalff, et al. · British Journal of Haematology · 11

PDF

Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?

2019 · Rachel E. Cooke, Rachel Koldej, et al. · Journal of Oncology · 6

PDF

Waldenström macroglobulinaemia and intestinal lymphangiectasia

2014 · Rachel E. Cooke, Renate M. Kalnins, et al. · British Journal of Haematology · 6

Acute respiratory distress syndrome precipitated by granulocyte colony-stimulating factor in undiagnosed Pneumocystis jirovecii pneumonia

2022 · Christopher Doig, Rachel Cooke, et al. · BMJ Case Reports · 4

PDF

Minimal change disease following autologous stem cell transplant for Hodgkin lymphoma

2025 · Patrick Leung, Timothy Pianta, et al. · BMJ Case Reports · 3

Real‐world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high‐risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry

2026 · Kenneth J. C. Lim, Elham Ashrafi, et al. · British Journal of Haematology · 2

Variation in immunoglobulin use and impact on survival in myeloma

2024 · Khai Li Chai, Cameron Wellard, et al. · eJHaem · 2

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement

2026 · Kenneth J. C. Lim, Maximilian Steinhardt, et al. · Blood Advances · 1

PDF

Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

2021 · Khai Li Chai, Cameron Wellard, et al. · Blood · 1

Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre

2022 · Constantine S. Tam, Gareth P. Gregory, et al. · Internal Medicine Journal

CD4+ T Cell Fate in Multiple Myeloma

2018 · Rachel Elizabeth Cooke, Jessica Chung, et al. · Blood

Abstract 11: Progression from newly diagnosed multiple myeloma to relapsed refractory multiple myeloma is associated with significant alterations in the CD4+ Treg population phenotype

2017 · Rachel Cooke, Hang Quach, et al. · Clinical Cancer Research

Works count: 17

Citation count: 172

H-index: 6

I10-index: 6